Ann: HEPATITIS C TRIAL UPDATE, page-32

My view is that anything they consider material and/or price sensitive will be reported. If you go back and look at the price sensitive tags on previous trial reports they have considered every move price sensitive. IE; each dosing and each DSMB review. I reckon they will change their tune a little on the dosing but will have to report the reviews. They are about as price sensitive and material as you can get. Lowering time line expectations seemed to be the main point. They have probably been inundated with calls from impatient people.